PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 7174588

Infant formula label review.

R W Barnes
View original source ↗Export metadata ↓

Abstract

The FDA review of infant formula labeling was conducted by a multi-disciplinary team composed of physicians, scientists, and experts in regulations and labeling. The review followed 2 tracks: the development of a general position of what would be necessary if we started with a blank label; and the purchase of many formulas and a critical review of information on the labels. An important part of the review was determining what information was available in the literature and using this information in assessing current practices and the effectiveness of present labeling. The review was divided into several major topics: introduction, definitions, historical perspectives, current regulatory situation, effectiveness of labeling, label review, other issues, and departmental initiatives. The labels review included product attributes, shelf life, retail and home storage instructions, and consumer preparation and use.

Explore related subjects

Food LabelingHumansInfantInfant FoodUnited StatesUnited States Food and Drug AdministrationJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R W Barnes. 1982. Infant formula label review.. https://pubmed.ncbi.nlm.nih.gov/7174588/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

FDA perspectives on health claims for food labels.

The U.S. Food and Drug Administration's regulatory authority over health claims was clarified in 1990 legislation known as the Nutrition Labeling and Education Act (NLEA). This law established mandatory nutrition labeling for most foods and placed restrictions on the use of food label claims characterizing the levels or health benefits of nutrients in foods. NLEA set a high threshold for the scientific standard under which the U.S. Food and Drug Administration (FDA) may authorize health claims, this standard is known as the significant scientific agreement (SSA) standard. Subsequent legislation known as the Food and Drug Administration Modernization Act (FDAMA) provided an alternative to FDA review of the health claim where an U.S. government scientific body other than FDA concluded that there is SSA for a substance/disease relationship. Courts have since extended the scope of health claims to include qualified health claims (QHC) that are health claims not substantiated on evidence that meets the level of SSA standard, but include a qualifying statement intended to convey to the consumer the level of evidence for the claim. FDA has responded by developing an evidence-based ranking system for scientific data to determine the level of evidence substantiating a health claim. The following is an overview of FDA's regulations and evidence-based method for evaluating health claims.

Food Labeling↗